Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Celldex Therapeutics (NASDAQ:CLDX) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02, Zacks reports. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Celldex Therapeutics Stock Down 1.6 %

Shares of Celldex Therapeutics stock traded down $0.32 during mid-day trading on Thursday, hitting $20.31. The stock had a trading volume of 339,813 shares, compared to its average volume of 908,390. The firm has a 50-day moving average of $24.05 and a two-hundred day moving average of $29.10. The firm has a market cap of $1.35 billion, a P/E ratio of -7.90 and a beta of 1.60. Celldex Therapeutics has a 12-month low of $20.25 and a 12-month high of $53.18.

Analyst Ratings Changes

A number of research firms have recently weighed in on CLDX. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, December 19th. UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.